扩张型心肌病遗传病因证据更新评估
BACKGROUND: Evidence of the diverse genetic architecture of dilated cardiomyopathy (DCM) continues to emerge and requires reassessment of the clinical relevance of implicated disease genes.…
要点
- 9个新评估基因列为高证据:BAG5、FLII、LMOD2、MYLK3、MYZAP、NRAP、PPA2、PPP1R13L、RPL3L。
核心结论
- DCM遗传架构快速扩展,高证据 curation 从5年前的19个增至35个。
- 基于证据的评估流程有助于DCM患者及家庭的基因信息临床解读。
研究设计与样本
- ClinGen DCM基因 curation 专家 panel 于2024-2025年重新召开,对既往已评估基因和新报道的基因-疾病-遗传模式关系进行重新评估。
主要发现
- 35个 curation 列为高证据等级(16 Definitive、10 Strong、9 Moderate),较前次评估增加16个。
- 9个新评估基因列为高证据:BAG5、FLII、LMOD2、MYLK3、MYZAP、NRAP、PPA2、PPP1R13L、RPL3L。
- 5个2019-2020年重新评估基因出现临床显著分类变化,除JPH2外均为低证据升级至高证据(PLEKHM2、PRDM16、TBX20、TNNI3K)。
- 29个基因-疾病-遗传模式 curation 列为Limited,4个列为No Known Disease Relationship并保持Disputed。
关键数值与推荐
- 高证据等级包括Definitive、Strong、Moderate三类,共35个 curation。
- JPH2分别curated为AD-Strong和AR-Limited;LDB3为AD-Limited和AR-Strong;MYBPC3为AD-Limited和AR-Limited;TNNI3为AD-和AR-Strong。
- MYBPC3-AR为新评估的遗传模式,列为Limited。
临床怎么用
- 临床解读DCM基因信息时可参考本更新评估的高证据基因列表,辅助患者及家庭的遗传咨询。
- 对常染色体隐性遗传模式的高证据基因应予以关注,尤其在新评估基因中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence of the diverse genetic architecture of dilated cardiomyopathy (DCM) continues to emerge and requires reassessment of the clinical relevance of implicated disease genes. Building on the 2019-2020 Clinical Genome Resource evaluation, the DCM gene curation expert panel reconvened in 2024-2025 to conduct a reassessment of genes in DCM. METHODS: The Clinical Genome Resource semiquantitative clinical validity classification framework was applied with specifications to DCM to classify genes into categories on the basis of strength of published evidence for a DCM phenotype. Previously curated genes were reassessed, and newly reported gene-disease-mode of inheritance (MOI) relationships, termed "curations," were evaluated. RESULTS: Sixty-eight genes were evaluated, inclusive of 72 unique gene-disease-MOI relationships across 51 previously evaluated and 17 newly assessed genes. Thirty-five curations were classified as high evidence (16 Definitive, 10 Strong, 9 Moderate), increasing by 16 from the prior assessment. Nine newly assessed genes were classified as high evidence: BAG5, FLII, LMOD2, MYLK3, MYZAP, NRAP, PPA2, PPP1R13L, and RPL3L. Twelve genes (11 newly appraised) were rated as high evidence with an autosomal recessive (AR) MOI. Five reevaluated genes from 2019-2020 had clinically significant changes in classification. Except for JPH2, for which curation was modified to separate autosomal dominant and AR MOI curations, clinically significant changes involved upgrades from low- to high-evidence categories (PLEKHM2, PRDM16, TBX20, TNNI3K), demonstrating the robustness of the Clinical Genome Resource gene curation process over time. An additional 29 gene-disease-MOI curations were classified as Limited, including 6 newly evaluated genes and 1 new MOI for a previously evaluated gene, MYBPC3-AR; 4 were classified as No Known Disease Relationship, and remained Disputed. Four previously evaluated genes were curated for both AD and AR MOIs: JPH2 (AD-Strong, AR-Limited), LDB3 (AD-Limited, AR-Strong), MYBPC3 (AD-Limited, AR-Limited), and TNNI3 (AD- and AR- Strong). CONCLUSIONS: With substantial new evidence, the genetic architecture of DCM has rapidly expanded. This updated assessment of genes reported in DCM yielded 35 high-evidence curations, an increase from 19 only 5 years ago. The results of this evidence-based evaluation process inform clinical interpretation of genetic information in the care of DCM patients and families.
引用
- Jordan E, Grover P, Parker P, et al. An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy. Circulation. 2026. PMID: 42708185. doi:10.1161/CIRCULATIONAHA.126.080302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。